Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kayla Smith

Nurse Practitioner, Family Jackson, MS Nurse Practitioner

NPI 1215422480 CMS profile 10481967

969 Lakeland Dr, Jackson, MS 39216

Open in the dashboard

General payments

$5,031

213 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kayla Smith of Jackson, MS is reported in the CMS Open Payments database as having received $5,031 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,298 50
2024 General $1,225 45
2023 General $1,139 49
2022 General $585 31
2021 General $784 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kayla Smith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kayla Smith were reported at $1,298. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kayla Smith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $784 $124 $35–$379 $132
2022 $585 $141 $44–$430 $149
2023 $1,139 $154 $49–$476 $160
2024 $1,225 $165 $51–$504 $164
2025 $1,298 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,001 32 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $979 39 payments
  3. Merck Sharp & Dohme Corporation $738 34 payments
  4. Alnylam Pharmaceuticals Inc. $357 16 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $280 11 payments
  6. Pfizer Inc. $243 15 payments
  7. Impulse Dynamics (USA) Inc. $216 10 payments
  8. Scpharmaceuticals Inc. $206 12 payments
  9. Novartis Pharmaceuticals Corporation $143 9 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $142 5 payments
  11. Other $726 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,926 210 payments
  2. Education $105 3 payments
Products named General payments · program years 2021–2025
  1. VERQUVO Cardiovascular $849 38 payments
  2. JARDIANCE Diabetes $689 30 payments
  3. FARXIGA $565 13 payments
  4. JARDIANCE Diabetes $309 11 payments
  5. WAINUA $306 10 payments
  6. AMVUTTRA $303 13 payments
  7. Kerendia $280 11 payments
  8. BRILINTA $216 11 payments
  9. FUROSCIX $206 12 payments
  10. VERQUVO Cardiovascular $176 9 payments
  11. Other $1,716 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,433

Median for Nurse Practitioner: 389

Drug cost

$1,794,821

Median for Nurse Practitioner: $21,885

Branded share of claims

35.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 20 $712,663
Entresto Sacubitril/Valsartan Brand 242 $303,896
Farxiga Dapagliflozin Propanediol Brand 245 $265,413
Jardiance Empagliflozin Brand 186 $213,946
Furoscix Furosemide Brand 20 $136,001
Verquvo Vericiguat Brand 95 $114,344
Corlanor Ivabradine Hcl Brand 15 $19,155
Isosorbide Dinit-Hydralazine Isosorbide Dinit/Hydralazine Brand 21 $6,024
Torsemide Generic 96 $3,291
Warfarin Sodium Generic 307 $3,064

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$49,391

Of which drugs: $76

Medicare patients

300

Average age 76

Services billed

2,724

132 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Atrial fibrillation 64%
Ischemic heart disease 63%
Arthritis 57%
Diabetes 47%
Chronic kidney disease 47%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, furosemide, up to 20 mg J1940 Office 44 210 $76

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $203
$203 245 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $199
$199 186 —
VERQUVO
  • Merck Sharp & Dohme Corporation $158
$158 95 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $135
$135 20 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $129
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record